ANRO Stock Forecast & Price Target

Alto Neuroscience is attractive fundamentally because its lead ALTO-207 program is backed by independent pramipexole data, including PAX-D, PRIME-PRAXOL, and a meta-analysis, which strengthens confidence that the fixed-dose, ondansetron-enabled approach can preserve efficacy while improving tolerability and faster titration. The investment case is also reinforced by a broad 2027 catalyst stack: three Phase 2b readouts, with ALTO-300 in 1H27, ALTO-100 in mid-2027, and PACE-1 in 2H27, plus planned Phase 3 starts for PACE-2 in early 2027 and PACE-3 in 2H27, potentially expanding the label and addressable TRD market. Financially, approximately $338 million of pro forma cash and runway through 2030 support execution across these milestones, while the biomarker platform and method-of-treatment patent estate through at least the mid-2040s create differentiated long-term commercial optionality.

Alto Neuroscience is viewed negatively because its core thesis still depends on unproven biomarker-driven psychiatry while prior execution has been weak: the Phase 2b ALTO-100 trial in MDD missed its primary endpoint, and even the cited adjunctive subgroup signals were based on sampled analyses that do not establish efficacy in bipolar depression. The company also faces rising operating strain, with R&D expense increasing to $22.1 million in 2Q26 from $13.1 million in 2Q25, the net loss widening to $27.6 million from $17.7 million, and ALTO-207 adding about $6.4 million of trial-launch costs. Beyond that, dependence on off-label substitution is operationally messy, ALTO-203 carries only a 5% PoS, and the model anticipates $150 million to $200 million of annual equity raises in 2027E–2029E, implying likely dilution.